Tuberculosis Diagnostics Market Introduction and Overview
According to SPER Market Research, the Global Tuberculosis Diagnostics Market is estimated to reach USD 4.18 billion by 2033 with a CAGR of 5.49%.
The report includes an in-depth analysis of the Global Tuberculosis Diagnostics Market, including market size and trends, product mix, applications, and supplier analysis. A type of bacteria known as Mycobacterium tuberculosis is the cause of the infectious disease tuberculosis. The patient's lungs are typically attacked by the infection. Other body parts like the spine and brain may also be affected by the infection. Blood and skin tests are two methods used to diagnose tuberculosis. The need for precise and effective diagnostic tests to stop the disorder's spread has grown due to its rising prevalence. In the upcoming years, this factor is anticipated to greatly increase the demand for tuberculosis diagnostics.
- August 2021: In order to identify Mycobacterium tuberculosis in blood samples, bioMérieux SA recently announced the introduction of an interferon gamma release assay in conjunction with a desktop immunoassay analyser.
- June 2023: The QuantiFERON-TB Gold Plus test is an interferon-gamma release assay (IGRA) that was utilized in blood collection tubes TB1 and TB2 to detect CD4 and CD8 T-cell responses, respectively.
Market Opportunities and Challenges
Public-private partnerships have a significant positive effect on the market because they facilitate the use of international healthcare standards to expand tuberculosis diagnosis. In an effort to lower the global burden of tuberculosis, governments have strengthened their policies regarding diagnosis. Since countries are becoming more and more aware of how serious the disease is, there will likely be a greater demand for diagnoses. The notable rise in the prevalence of this illness in emerging nations is one of the most important factors supporting the market's expansion.
A few restrictions could impede market expansion during the projected period, notwithstanding the urgent and growing need for sophisticated diagnostic technologies for these illnesses. Throughout the course of the market forecast period, for example, certain technological challenges related to tuberculosis diagnostics may pose a significant restraint. One of the main factors impeding the market's overall growth is the greater level of technical difficulty involved in developing these diagnostic tools. The most widely used TB diagnostic test had drawbacks, including low sensitivity, and was sputum smear microscopy. The elderly, children, and HIV-positive patients are susceptible to false positive results. It cannot be utilized to identify extra pulmonary tuberculosis, either.
Market Competitive Landscape
Key market players use expansions, partnerships, mergers and acquisitions, and new product launches as vital business strategies to broaden their global reach. The major players in the Global Tuberculosis Diagnostics Market include: Abbott Laboratories, Becton, BioMérieux SA, Cepheid, Dickinson and Company, F. Hoffmann-La Roche AG, Hain Lifescience GmbH, Hologic, QIAGEN GmbH, Thermo Fisher Scientific.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Test Types, By End- User, By Disease Type
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Abbott Laboratories, Becton, BioMérieux SA, Cepheid, Dickinson and Company, F. Hoffmann-La Roche AG, Hain Lifescience GmbH, Hologic, Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc
|
COVID-19 Impact on Global Tuberculosis Diagnostics Market
During the COVID-19 pandemic, there was a decrease in the market for diagnostic products for tuberculosis. This component resulted from a notable drop in the number of patients receiving TB diagnoses. The rate of tuberculosis testing decreased in high-burden areas of the global market as a result of the COVID-19 pandemic. Even though tuberculosis is highly contagious, early on in the pandemic, funding for programs that diagnose tuberculosis was redirected to combat the coronavirus pandemic. 2020 saw the shift in healthcare providers, testing equipment, labs, and health centres from treating tuberculosis to treating COVID-19 due to an increase in cases globally.
Key Target Audience
- Diagnostics Laboratories
- Hospitals
- National TB control programmes (NTP)
- HIV and TB programme managers
Our in-depth analysis of the Tuberculosis Diagnostics Market includes the following segments:
| By Test Type: | Culture-based Diagnostics, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Radiographic Method,Sputum Smear Microscopy |
| By End Use: | Diagnostics Laboratories Hospitals |
| By Disease Stage: | Latent Tuberculosis Active Tuberculosis |
Key Topics Covered in the Report
- Global Tuberculosis Diagnostics Market Size (FY’2023-FY’2033)
- Overview of Global Tuberculosis Diagnostics Market
- Segmentation of Global Tuberculosis Diagnostics Market By Test Types (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Culture-based Diagnostics, Sputum Smear Microscopy)
- Segmentation of Global Tuberculosis Diagnostics Market By End-user (Diagnostics Laboratories and Hospitals)
- Segmentation of Global Tuberculosis Diagnostics Market By Disease Stage (Latent Tuberculosis and Active Tuberculosis)
- Statistical Snap of Global Tuberculosis Diagnostics Market
- Expansion Analysis of Global Tuberculosis Diagnostics Market
- Problems and Obstacles in Global Tuberculosis Diagnostics Market
- Competitive Landscape in the Global Tuberculosis Diagnostics Market
- Impact of COVID-19 and Demonetization on Global Tuberculosis Diagnostics Market
- Details on Current Investment in Global Tuberculosis Diagnostics Market
- Competitive Analysis of Global Tuberculosis Diagnostics Market
- Prominent Players in the Global Tuberculosis Diagnostics Market
- SWOT Analysis of Global Tuberculosis Diagnostics Market
- Global Tuberculosis Diagnostics Market Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Tuberculosis Diagnostics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Tuberculosis Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tuberculosis Diagnostics Market
7. Global Tuberculosis Diagnostics Market, By Test Type (USD Million)
7.1. Global Tuberculosis Diagnostics Market Value Share and Forecast, By Test Type 2023-2033
7.2. Culture-based Diagnostics,
7.3. Diagnostic Laboratory Methods,
7.4. Nucleic Acid Testing,
7.5. Phage Assay,
7.6. Radiographic Method,
7.7. Sputum Smear Microscopy
8. Global Tuberculosis Diagnostics Market, By End Use (USD Million)
8.1. Global Tuberculosis Diagnostics Market Value Share and Forecast, By End Use 2023-2033
8.2. Diagnostics Laboratories
8.3. Hospitals
9. Global Tuberculosis Diagnostics Market, By Disease Stage (USD Million)
9.1. Global Tuberculosis Diagnostics Market Size Value Share and Forecast, By Disease Stage 2023-2033
9.2. Latent Tuberculosis
9.3. Active Tuberculosis
10. Global Tuberculosis Diagnostics Market, Forecast, 2019-2033 (USD Million)
10.1. Global Tuberculosis Diagnostics Market Size and Market Share
11. Global Tuberculosis Diagnostics Market, By Test Type 2019-2033 (USD Million)
11.1. Global Tuberculosis Diagnostics Market Size and Market Share, By Test Type (2019-2026)
11.2. Global Tuberculosis Diagnostics Market Size and Market Share, By Test Type (2027-2033)
12. Global Tuberculosis Diagnostics Market, By End Use 2019-2033 (USD Million)
12.1. Global Tuberculosis Diagnostics Market Size and Market Share, By End Use (2019-2026)
12.2. Global Tuberculosis Diagnostics Market Size and Market Share, By End Use (2027-2033)
13. Global Tuberculosis Diagnostics Market, By Disease Type, 2019-2033 (USD Million)
13.1. Global Tuberculosis Diagnostics Market Size and Market Share, By Disease Type (2019-2026)
13.2. Global Tuberculosis Diagnostics Market Size and Market Share, By Disease Type (2027-2033)
14. Global Tuberculosis Diagnostics Market, By Region, 2019-2033 (USD Million)
14.1. Global Tuberculosis Diagnostics Market Size and Market Share, By Region (2019-2026)
14.2. Global Tuberculosis Diagnostics Market Size and Market Share, By Region (2027-2033)
14.3. Asia-Pacific
14.3.1. Australia
14.3.2. China
14.3.3. India
14.3.4. Japan
14.3.5. South Korea
14.3.6. Rest of Asia-Pacific
14.4. Europe
14.4.1. France
14.4.2. Germany
14.4.3. Italy
14.4.4. Spain
14.4.5. United Kingdom
14.4.6. Rest of Europe
14.5. Middle East and Africa
14.5.1. Kingdom of Saudi Arabia
14.5.2. United Arab Emirates
14.5.3. Rest of Middle East & Africa
14.6. North America
14.6.1. Canada
14.6.2. Mexico
14.6.3. United States
14.7. Latin America
14.7.1. Argentina
14.7.2. Brazil
14.7.3. Rest of Latin America
15. Company Profile
15.1. Abbott Laboratories
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary
15.1.4. Recent developments
15.2. Becton
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary
15.2.4. Recent developments
15.3. BioMérieux SA
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary
15.3.4. Recent developments
15.4. Cepheid
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary
15.4.4. Recent developments
15.5. Dickinson and Company
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary
15.5.4. Recent developments
15.6. F. Hoffmann-La Roche AG
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary
15.6.4. Recent developments
15.7. Hain Lifescience GmbH
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary
15.7.4. Recent developments
15.8. Hologic
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary
15.8.4. Recent developments
15.9. QIAGEN GmbH
15.9.1. Company details
15.9.2. Financial outlook
15.9.3. Product summary
15.9.4. Recent developments
15.10. Thermo Fisher Scientific
15.10.1. Company details
15.10.2. Financial outlook
15.10.3. Product summary
15.10.4. Recent developments
15.11. Others
16. List of Abbreviations
17. Reference Links
18. Conclusion
19. Research Scope